Johannes Jacob Pieter Kastelein
Known title: Chief Scientific OfficerCIK: 0002000389
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
Transaction History
| NAMSW | ▲ Buy | Option Exercise | 50,246 | — | 9/30/2026 | View on chart |
| NAMSW | ▼ Sell | Open Market | 50,246 | $1.3M | 9/30/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 125,000 | — | 8/24/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 125,000 | $3.4M | 8/24/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 101,409 | — | 3/9/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 101,409 | $3.1M | 3/9/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 94,124 | — | 3/6/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 94,124 | $2.9M | 3/6/2026 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 104,467 | — | 3/5/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 104,467 | $3.2M | 3/5/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 14,692 | $514K | 2/20/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 30,789 | $1.1M | 2/20/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 25,500 | — | 1/7/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 6,000 | $200K | 1/5/2026 | View on chart |
| NAMS | ▼ Sell | Open Market | 42,342 | $1.1M | 8/22/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 7,658 | $195K | 8/22/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 50,000 | $1.2M | 8/21/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 45,481 | $0 | 3/26/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 19,302 | $0 | 3/26/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 150,000 | — | 3/24/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 34,000 | — | 1/7/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 201,673 | — | 3/26/2024 | View on chart |
| NAMS | ▼ Sell | Tax Withholding | 11,197 | $254K | 3/26/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 190,476 | $4.1M | 3/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy
NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.
NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy. NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.